세계의 마이코플라스마 진단 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The global demand for Mycoplasma Diagnostics Market is presumed to reach the market size of nearly USD 4 Billion by 2032 from USD 1.98 Billion in 2023 with a CAGR of 8.12% under the study period 2024 - 2032.

Mycoplasma diagnostics refers to laboratory tests and methods used to detect and identify mycoplasma species, a group of bacteria that can infect humans, plants, and animals. Mycoplasma contamination in cell cultures, biopharmaceuticals, vaccines, and other biological products can compromise research integrity, product quality, and safety, making accurate and reliable diagnostics essential. Mycoplasma detection methods may include culture-based techniques, polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), DNA staining, and nucleic acid amplification tests (NAATs).

MARKET DYNAMICS

The increasing prevalence of mycoplasma infections in humans and animals and the rising awareness of the potential health risks associated with these infections drive the demand for accurate & reliable diagnostic tests. Mycoplasma species are known to cause a wide range of respiratory, genitourinary, and systemic diseases, making timely and accurate diagnosis essential for appropriate treatment and infection control measures. Additionally, the growing demand for point-of-care and rapid diagnostic tests in clinical settings, driven by the need for quick and accurate diagnosis of infectious diseases, fuels the development and commercialization of mycoplasma diagnostic assays. Moreover, advancements in molecular and serological testing technologies, such as polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and nucleic acid amplification tests (NAATs), enhance the sensitivity, specificity, and turnaround time of mycoplasma diagnostic tests, improving patient outcomes and reducing healthcare costs.

Furthermore, the increasing adoption of mycoplasma diagnostics in veterinary medicine and animal husbandry practices, driven by the need to control mycoplasma infections in livestock and companion animals, contributes to market growth. With mycoplasma infections posing significant economic losses in the agriculture and aquaculture industries, the demand for accurate & efficient diagnostic tools to manage these infections continues to rise. Moreover, the emergence of novel mycoplasma species and antibiotic-resistant strains further underscores the importance of continuously innovating and developing mycoplasma diagnostics to address evolving diagnostic challenges. However, advancements in alternative diagnostic technologies and new testing methods may challenge the mycoplasma diagnostics market growth in the coming years, as these innovations could offer faster, more cost-effective, or more accurate diagnostic solutions.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of mycoplasma diagnostics. The growth and trends of mycoplasma diagnostics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the mycoplasma diagnostics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Product

• Kits & Reagents
• Instruments
• Software & Services

By Technology

• PCR
• Immunoassay (ELISA, RIA)
• DNA Staining
• Microbial Culture Techniques
• Others

By End-User

• Hospitals
• Diagnostic Laboratories
• Clinics
• Others

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Mycoplasma Diagnostics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Mycoplasma Diagnostics market include Merck & Co., Inc., F. Hoffmann-La Roche AG, Agilent Technologies, Sartorius AG, Savyon Diagnostics, Takara Bio Inc. (Takara Holding Company Inc.), Lonza Group, Charles River Laboratories International, Inc., Thermo Fisher Scientific Inc., PromoCell GmbH. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. MYCOPLASMA DIAGNOSTICS - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Product
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By End-user
  • 3.7.4 Market Attractiveness Analysis By Region

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY PRODUCT

• 5.1. Overview By Product
• 5.2. Historical and Forecast Data
• 5.3. Analysis By Product
• 5.4. Kits & Reagents Historic and Forecast Sales By Regions
• 5.5. Instruments Historic and Forecast Sales By Regions
• 5.6. Software & Services Historic and Forecast Sales By Regions

6. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY TECHNOLOGY

• 6.1. Overview By Technology
• 6.2. Historical and Forecast Data
• 6.3. Analysis By Technology
• 6.4. PCR Historic and Forecast Sales By Regions
• 6.5. Immunoassay (ELISA, RIA) Historic and Forecast Sales By Regions
• 6.6. DNA Staining Historic and Forecast Sales By Regions
• 6.7. Microbial Culture Techniques Historic and Forecast Sales By Regions
• 6.8. Others Historic and Forecast Sales By Regions

7. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY END-USER

• 7.1. Overview By End-user
• 7.2. Historical and Forecast Data
• 7.3. Analysis By End-user
• 7.4. Hospitals Historic and Forecast Sales By Regions
• 7.5. Diagnostic Laboratories Historic and Forecast Sales By Regions
• 7.6. Clinics Historic and Forecast Sales By Regions
• 7.7. Others Historic and Forecast Sales By Regions

8. GLOBAL MYCOPLASMA DIAGNOSTICS MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE MYCOPLASMA DIAGNOSTICS COMPANIES

• 9.1. Mycoplasma Diagnostics Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF MYCOPLASMA DIAGNOSTICS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Merck & Co. Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. F. Hoffmann-La Roche AG
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Agilent Technologies
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Sartorius AG
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. Savyon Diagnostics
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Takara Bio Inc. (Takara Holding Company Inc.)
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Lonza Group
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Charles River Laboratories International Inc.
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Thermo Fisher Scientific Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. PromoCell GmbH
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of private companies